Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132555 | 0.96 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL4131152 | 0.94 | TLR7 (0.61) | TLR7 | |
| SCHEMBL2837664 | 0.94 | TLR7 (0.68) | TLR7 | |
| Hydrochloric Acid SCHEMBL3360874 | 0.93 | TLR7 (0.67) | TLR7 | |
| Bromide SCHEMBL3363812 | 0.93 | TLR7 (0.67) | TLR7 | |
| SCHEMBL13798673 | 0.93 | TLR7 (0.68) | TLR7 | |
| SCHEMBL9935765 | 0.93 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL9936854 | 0.93 | TLR7 (0.62) | TLR7 | |
| SCHEMBL2390244 | 0.93 | TLR7 (0.68) | TLR7 | |
| SCHEMBL16256477 | 0.92 | TLR7 (0.68) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | claimed |
| EP-1928876-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | claimed |
| WO-2007031726-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | claimed |
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| EP-1928876-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007031726-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143400-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | IFNG, IFNAR1, IRF3 | TLR7 101/4885TLR8 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.